Basilea announces change in its management structure
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea announces change in its management structure
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, October 3, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN)
announced today that Ronald Scott has been appointed Chief Operating Officer
(COO) of Basilea Pharmaceutica International Ltd.
Ronald Scott was appointed Chief Financial Officer at the company's inception.
In addition to finance, business development, investor relations and public
relations, he now assumes responsibility for commercial activities,
manufacturing and corporate services with the respective departments retaining
their heads. He will continue as ad interim Chief Financial Officer. In line
with Basilea's strategic focus to bring innovative new drugs to the market,
research and development, including Basilea's operations in China, will continue
to report directly to Chief Executive Officer, Dr. Anthony Man.
Anthony Man commented: "Ron has demonstrated his management skills in finance
and business development as attested by Basilea's significant transactions
achieved under his leadership. We are committed to bring innovative new
medicines to patients addressing resistance and non-response to current
treatment options in the hospital and specialty care setting. This change allows
me to focus on our highest business priorities associated with Toctino,
ceftobiprole, isavuconazole together with our exciting new Gram-negative
antibiotic and anti-cancer drug development as well as on our mid-to-long term
strategy to build value through R&D innovation."
The company is committed to principles of good corporate governance. Considering
these evolving principles, Dr. Anthony Man and Ronald Scott, as executive board
members, have decided to step down from the Board of Directors of Basilea
Pharmaceutica Ltd. with immediate effect. The Basilea Board of Directors is thus
fully composed of non-executive board members.
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX:BSLN). Basilea Pharmaceutica International Ltd.'s
fully integrated research and development operations are focused on antibiotics,
antifungals and oncology drugs, as well as on the development of dermatology
drugs, targeting the medical challenge of resistance and non-response to current
treatment options in the hospital and specialty care setting.
Basilea is currently marketing Toctino® (alitretinoin), the only approved
treatment for adults with severe chronic hand eczema unresponsive to potent
topical corticosteroids, in Denmark, Finland, France, Germany, Norway,
Switzerland and the United Kingdom and has appointed distributors for Toctino®
in other selected European markets, Canada, Israel, Mexico and the Republic of
Korea. A phase III clinical program on alitretinoin for the treatment of severe
chronic hand eczema is ongoing in the U.S.
For its phase III compound isavuconazole, a potential best-in-class azole
antifungal for the treatment of life-threatening invasive fungal infections, the
company has entered into a license, co-development and co-promotion agreement
with Astellas Pharma Inc.
In addition, Basilea is developing ceftobiprole, a late-stage novel anti-MRSA
(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin
antibiotic, for the first-line treatment of potentially life-threatening
resistant bacterial infections. Ceftobiprole has a broad coverage of both Gram-
positive bacteria, including MRSA, and many clinically important Gram-negative
bacteria such as Pseudomonas spp.
Basilea's BAL30072, a novel antibiotic for the treatment of resistant Gram-
negative infections, and the oncology drug BAL101553 for the treatment of drug-
resistant cancers are in phase I clinical testing.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, Ph.D. | Barbara Zink, Ph.D., MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1102 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.
--- End of Message ---
Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
Press release (PDF) :
http://hugin.info/134390/R/1551417/477822.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
[HUG#1551417]
Unternehmensinformation / Kurzprofil:
Datum: 03.10.2011 - 07:15 Uhr
Sprache: Deutsch
News-ID 71548
Anzahl Zeichen: 6841
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 310 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea announces change in its management structure"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
